Organ mass analysis (Fig. 6 C) revealed that compared with the NAFLD + DMSO group, AMPK-IN-3 treatment further increased the weights of retroperitoneal fat, liver, and kidneys. This evidence concerns the gene PRKAA1 and metabolic dysfunction-associated steatotic liver disease.